Infignos Media -- buyersUSA Consulting
NOW PLAYING
15 Radio Streams
Click Here
The Downtown Market
Advertise Here

From Entertainment and Media - Magazines

Brought to you by East Alabama Regional Planning Commission

Quintard Tower, Suite 300 1130 Quintard Avenue,Anniston, AL 36201 Phone Toll Free - 800-239-6741,Local - 256-237-6741,Fax - 256-237-6763

Erectile Dysfunction

Study Sheds New Light on the Progression and Invasiveness of Ductal Breast Cancer

Tue, 16 Oct 2012 14:56:46 EST

Results published in The American Journal of Pathology

Philadelphia, PA – Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis). A new study has found that despite an enormous degree of intercellular heterogeneity in both DCIS and IDC, the evolution from noninvasive to invasive disease is determined by recurrent patterns of genomic imbalances in most cases. This study is published online in advance of the November issue of The American Journal of Pathology.

'For patients with cancer, the transition from locally controlled disease to a disseminated stage and metastases is probably the most critical threshold, because that transition makes surgical intervention considerably less likely to succeed,' says lead investigator Thomas Ried, Section Chief, Genetics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD. 'We looked at gene copy number changes during the transition from DCIS to IDC and, if so, what patterns of genetic imbalances drive this process.'

The study was based on archived clinical samples for which the co-occurrence of DCIS and IDC in the same patient had been tracked at the National Naval Medical Center. It was led by researchers from the NCI and also included researchers from the National Center for Biotechnology Information, the National Naval Medical Center, Bethesda, MD, and Carnegie Mellon University, Pittsburgh, PA.

Investigators compared the genetic makeup of individual cells from 13 patients with DCIS and IDC and analyzed the gain or loss of specific genes that are frequently affected in DCIS and IDC. These genes included cancer promoting oncogenes and cancer suppressing tumor suppressor genes. Fluorescence in situ hybridization (FISH) probe panels, which use fluorescent copies or clones of the relevant DNA sections to identify gene copy numbers, were hybridized to intact cells prepared from histomorphologically identified areas from lesions from several patients. Subsequent hybridizations of multicolor probe panels resulted in multiplexing of probes that further allowed for simultaneous analysis of copy numbers of five oncogenes and three tumor suppressor genes within each cell analyzed.

A high degree of chromosomal instability from one cell to another was observed, reflected by the fact that identical signal clones were only present in less than 20% of the cells. Despite this instability, the distribution of gains and losses in most cases was consistent with known genetic aberration profiles for breast cancer, and investigators found patterns consistent with non-random distribution of genomic imbalances. CDH1, a tumor suppressor that triggers cancer invasion and metastases upon reduced expression, was most commonly lost in DCIS and IDC. MYC, a strong oncogene that drives cell proliferation and regulates cell growth and differentiation, was most frequently gained from DCIS to IDC. MYC appears to play a major role in the transition from 'in situ' to invasive breast disease.

'DCIS and IDCs are genetically related lesions as they both have similar imbalance patterns. However, according to their aberration patterns, the DCIS lesions are far further advanced than other precursor lesions with more stable genomes, such as colorectal polyps or cervical dysplasias,' notes Dr. Ried. 'The considerable degree of intercellular heterogeneity in the DCIS convincingly attests to the fact that chromosomal instability precedes the transition to invasive disease.'

Dr. Ried observes that the advanced aberration profiles of DCIS associated with IDC make it unlikely that progression to invasive disease can be prevented with measures other than surgery, radiation, and adjuvant hormonal therapy.

'This of course raises the question of what precisely determines this critical transition between pre-invasive and invasive disease. Identifying the differences in the full catalog of genes in DCIS and IDC could have the potential of identifying a gene expression signature that is ultimately responsible for invasion and progression,' he concludes.

# # #

Notes for editors
'Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity, yet conserved genomic imbalances and gain of MYC during progression,' by Kerstin Heselmeyer-Haddad, Lissa Y. Berroa Garcia, Amanda Bradley, et al. DOI: http://dx.doi.org/10.1016/j.ajpath.2012.07.012. It appears in The American Journal of Pathology, Volume 181, Issue 5 (November 2012) published by Elsevier.

Full text of the article is available to credentialed journalists upon request; contact David Sampson at +1-215-239-3171 or ajpmedia@elsevier.com. Journalists wishing to interview the authors may contact the NCI Press Officers at +1-301-496-6641, +1-301-451-7440 (fax) or ncipressofficers@mail.nih.gov.

About The American Journal of Pathology
The American Journal of Pathology (http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology – over 38,000 cites in 2011 – with an Impact Factor of 4.890 according to 2011 Journal Citation Reports®, Thomson Reuters.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


Source: WebWire



From Our Blogs

Naked Man Plus Home for Sale Equals Lots of Views

Adorable funny video featuring local actors...

Back-to-School Shopping on a Budget

To make the back-to-school season easier and more affordable, do get your game plan together.

How to Network Your Way to a Great New Job

Social media is not a substitute for face-to-face communication.

This School Year, Raise Grades with Online Learning Tools

There are great ways you can help make this school year the best one yet.


Sign up for our weekly newsletter.

Our Website Sponsors

Artificial Limb & Brace

At Artificial Limb & Brace Center, it is our mission to provide people with orthotic and prosthetic services and products using the most reliable technology to give them the best results possible. Call us at 256-236-2562.

The Party Center

Everything you need for your next party! Specializing in items for your birthdays, weddings, anniversaries, and all holidays and special occasions. Located at 1716 Hamric Drive East in Oxford. Call 256-831-4449.

Transformation Technologies

Improve your golf scores. View our free 16 minute golf course at golf.transformationsolutions.com

Oxford Lumber

Neighborhood service and warehouse prices since 1958. We're also proud to own and operate Roanoke Ace Home Center, Talladega Ace Home Center and Jacksonville Home Center. Oxford Lumber is located at 1400 Barry Street. Call 256-831-0540

Frontera Bar & Grill

Mexican quisine at it's finest. For lunch, dinner or take out, visit Frontera Bar & Grill 1750 Hamric Dr E Oxford, AL 36203? (256) 835-9905